Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase

Pfizer (PFE) reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 cents per share. The company had recorded an adjusted loss of 17 cents per share in the year-ago quarter. Revenues came in at $17.7 billion, up 31% from the year-ago quarter on a reported basis, reflecting an operational increase of 32% and a negative currency impact of 1%. Total revenues significantly beat the Zacks Consensus Estimate of $15.19 billion. Higher sales of Pfizer's ke ...